Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow‐up

Erik Ahlstrand(Örebro University), Björn Andréasson(NU Hospital Group), Anna Ravn Landtblom(Karolinska University Hospital), Maria Liljeholm(University Hospital of Umeå), Helna Pettersson(NU Hospital Group), Stefan Scheding, Marie Lindgren(Umeå University), Jan Samuelsson(Karolinska University Hospital)
European Journal Of Haematology
December 21, 2019
10.1111/ejh.13373
Cited by 13

Related Papers

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
|Blood|2011|340
Treatment of Anemia in Myelodysplastic Syndromes With Granulocyte Colony-Stimulating Factor Plus Erythropoietin: Results From a Randomized Phase II Study and Long-Term Follow-Up of 71 Patients
|Blood|1998|306
Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms
|Journal of Clinical Oncology|2011|244
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194